Suchergebnisse - "Roth, Eli M"

PubPharm (72)

1

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

enthalten in: Journal of clinical lipidology | 2020

von Roth, E. | Kastelein, J. | Cannon, C. | +9

2

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

enthalten in: Journal of clinical lipidology | 2019

von Robinson, J. | Farnier, M. | Kastelein, J. | +9

3

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin

enthalten in: The Journal of clinical endocrinology and metabolism | 2019

von Müller-Wieland, D. | Rader, D. | Moriarty, P. | +7

4

Alirocumab for low-density lipoprotein cholesterol lowering

enthalten in: Future cardiology | 2019

von Roth, E.

5

PCSK9 Inhibitors : Mechanism of Action, Efficacy, and Safety

enthalten in: Reviews in cardiovascular medicine | 2018

von Roth, E. | Davidson, M.

6

A safety evaluation of evolocumab

enthalten in: Expert opinion on drug safety | 2018

von Roth, E.

7

Antidrug Antibodies in Patients Treated with Alirocumab

enthalten in: The New England journal of medicine | 2017

von Roth, E. | Goldberg, A. | Catapano, A. | +6

CommentOn: N Engl J Med. 2017 Apr 20;376(16):1517-1526. - PMID 28304227

8

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin : ODYSSEY CHOICE I

enthalten in: Atherosclerosis | 2016

von Roth, E. | Moriarty, P. | Bergeron, J. | +6

CommentIn: Atherosclerosis. 2016 Nov;254:300-302. - PMID 27745881

9

Alirocumab for hyperlipidemia : ODYSSEY Phase III clinical trial results and US FDA approval indications

enthalten in: Future cardiology | 2016

von Roth, E.

10

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method : analysis of 3 randomized trials versus placebo

enthalten in: Lipids in health and disease | 2016

von Toth, P. | Hamon, S. | Jones, S. | +7

1
2
3
4
5
6
7
8
Nächster »
[8]